ReviewFrontiers in digital health2025
Early detection of chronic kidney disease using deep learning: a Mini review.
Review in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Explainable AI in breast cancer ultrasound imaging: current developments and challenges.Frontiers in digital health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic Kidney Disease (CKD) remains a major contributor to global morbidity, often progressing unnoticed until advanced stages when treatment options become limited and costly. Recent advances in deep learning have reshaped early CKD assessment by enabling the analysis of complex imaging, clinical, and longitudinal laboratory datasets. This mini-review synthesizes findings from studies published between 2020 and 2025, highlighting models that report diagnostic accuracies ranging from 88% to 99.96%, AUC values reaching 0.93, and ensemble architectures capable of forecasting CKD 6 to12 months before clinical diagnosis with up to 99.31% accuracy. These systems spanning Convolutional Neural Networks (CNNs), Long Short-Term Memory networks (LSTMs), hybrid CNN-LSTM designs, and transfer-learning frameworks have demonstrated clear advantages over conventional diagnostic markers such as serum creatinine and eGFR. Despite impressive numerical performance, key limitations persist: class imbalance in early-stage CKD, restricted generalizability due to single-centre datasets, variability in imaging quality, and the limited interpretability of high-capacity neural networks. As deep learning continues to advance, robust external validation, transparent model explanations, and multi-institutional datasets will be essential to support safe and reliable clinical integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.